1. Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas 
M.C. Pietanza, MD, Matthew D. Hellmann, MD, John J. Fiore, MD, Stephanie Smith-Marrone, MD, Ethan M. Basch, MD, Lawrence H. Schwartz, MD, Michelle S. Ginsberg, MD, Marwan Shouery, MS, Samantha K. Newman, MD, Mary Shaw, BA, Lauren J. Rogak, MA, Alex E. Lash, MD, Patrick Hilden, MS, Mark G. Kris, MD 
Journal of Thoracic Oncology 
Volume 11, Issue 6, Pages (June 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
PPB (paclitaxel, pemetrexed, and bevacizumab) CONSORT diagram.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Best change in measurable lesion size from baseline for 42 patients with evaluable indicator lesions: waterfall plot. KRAS, Kirsten rat sarcoma viral oncogene homolog gene.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Overall progression-free and overall survival from the date of start of PPB (paclitaxel, pemetrexed, and bevacizumab) treatment (N = 44).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions